Clinical trials: SARS-CoV-2
Biological Availability
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
The purpose of this study is to estimate the relative bioavailability (rBA) of nirmatrelvir/ritonavir oral powder in 3 different food vehicles relative to the Paxlovid® tablets under fasted condition in healthy adult…
- Trial name
- NCT05544786
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/Ritonavir
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
COVID, Corona Virus Infection
Seroprevalence of SARS-Cov-2 Antibodies in Children
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to…
- Conditions
- COVID, Corona Virus Infection, Multisystem Inflammatory Syndrome in Children
- Trial name
- NCT04347408
- Testing
- Covid-19 Antibody testing (IgG and IgM), Blood Storage
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Covid19
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT04481685
- Testing
- ATI-450
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Lung Transplant Recipient, SARS-CoV-2
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes.
- Conditions
- Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
- Trial name
- NCT05280158
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
COVID-19 Vaccines
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind study designed to evaluate the safety, immunogenicity and efficacy of ARCT-154 in adult participants to be enrolled in Vietnam.
- Trial name
- ARCT-154-01 (NCT05012943)
- Testing
- ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Astra Zeneca COVID-19 vaccine
- Where
- 3 sites in Vietnam
- Volunteers
- 19,474 people, healthy volunteers welcome
- Sponsor
- Vinbiocare Biotechnology Joint Stock Company
SARS-CoV-2
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.
- Trial name
- NCT04728347
- Testing
- ARCT-021
- Where
- Singapore
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
- Trial name
- NCT04397757
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
COVID-19, Sars-CoV2
Rapid, Onsite COVID-19 Detection
The purpose of this research study is to evaluate and improve a rapid COVID-19 test. The test is designed to identify people who are most contagious and likely to spread the virus to others.
- Trial name
- NCT04460690
- Testing
- Rapid Onsite COVID-19 Detection
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Wisconsin, Madison
COVID-19, COVID
Early CPAP in COVID-19 Confirmed or Suspected Patients
There is surge in COVID infected patients in New York City with a shortage of hospital beds, ICU beds and ventilators. Strategies to reduce the need for all of the above are immediately needed.
- Conditions
- COVID-19, COVID, Coronavirus
- Trial name
- PAP-COVID (NCT04390191)
- Testing
- Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
COVID-19
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04640168
- Testing
- Baricitinib, Dexamethasone, Remdesivir
- Where
- 72 sites in United States, Japan and 3 more
- Volunteers
- 1,010 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, SARS-CoV-2 PNEUMONIA
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Coronavirus is an acute viral disease with prevailing upper respiratory tract infections caused by the RNA-containing virus of the genus Betacoronavirus of the Coronaviridae family.
- Conditions
- Covid19, SARS-CoV-2 PNEUMONIA, COVID-19
- Trial name
- COVID-19EXO (NCT04491240)
- Testing
- EXO 1 inhalation, EXO 2 inhalation
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- State-Financed Health Facility "Samara Regional Medical Center Dinasty"
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
Covid19
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
- Trial name
- ARCADIA (NCT04516759)
- Testing
- AZD1656
- Where
- 30 sites in Czechia, Romania and 1 more
- Volunteers
- 170 people
- Sponsor
- St George Street Capital
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pneumonia
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
This research study is being done to determine the appropriate dose of steroids and the appropriate duration for steroid use to reduce inflammation in severe pneumonia needing a form of breathing support.
- Trial name
- NCT03852537
- Testing
- Methylprednisolone, Usual Care
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Mayo Clinic
Covid19, Vaccine Refusal
Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate
The purpose of the study is to assess the effectiveness of the HALT COVID Ambassador educational outreach program on increasing likelihood to vaccinate against COVID-19
- Trial name
- NCT04930965
- Testing
- Community health worker engagement
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Tulane University
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.